Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Hold rating on Edwards Lifesciences while lowering the price target from $66 to $63.
October 25, 2024 | 4:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Canaccord Genuity has maintained a Hold rating on Edwards Lifesciences and lowered the price target from $66 to $63, indicating a slightly less optimistic outlook.
The Hold rating suggests a neutral stance, but the lowered price target indicates a slightly negative outlook on the stock's short-term performance. This could lead to a minor decrease in stock price as investors adjust expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100